Narrative Review: Update on the Molecular Diagnosis of Fragile X Syndrome
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24119206 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Cristian-Gabriel Ciobanu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetics Department, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No 16, 700115 Iasi, Romani…. Hauptthemen laut MEDLINE: Fragile X Syndrome. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The diagnosis and management of fragile X syndrome (FXS) have significantly improved in the last three decades, although the current diagnostic techniques are not yet able to precisely identify the number of repeats, methylation status, level of mosaicism, and/or the presence of AGG interruptions. A high number of repeats (>200) in the fragile X messenger ribonucleoprotein 1 gene (FMR1) results in hypermethylation of promoter and gene silencing. The actual molecular diagnosis is performed using a Southern blot, TP-PCR (Triplet-Repeat PCR), MS-PCR (Methylation-Specific PCR), and MS-MLPA (Methylation-Specific MLPA) with some limitations, with multiple assays being necessary to completely characterise a patient with FXS. The actual gold standard diagnosis uses Southern blot; however, it cannot accurately characterise all cases. Optical genome mapping is a new technology that has also been developed to approach the diagnosis of fragile X syndrome. Long-range sequencing represented by PacBio and Oxford Nanopore has the potential to replace the actual diagnosis and offers a complete characterization of molecular profiles in a single test. The new technologies have improved the diagnosis of fragile X syndrome and revealed unknown aberrations, but they are a long way from being used routinely in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Genetics Department, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No 16, 700115 Iasi, Romania.
- Investigatii Medicale Praxis, St. Moara de Vant No 35, 700376 Iasi, Romania.
- Medical Genetics Department, "Saint Mary" Emergency Children's Hospital, St. Vasile Lupu No 62, 700309 Iasi, Romania.
- Pediatrics Department, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No 16, 700115 Iasi, Romania.
- Department of Biochemistry, Faculty of Dental Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No 16, 700115 Iasi, Romania.
ORCID-Profile: Cristian-Gabriel Ciobanu, Irina Nucă, Roxana Popescu, Cosmin-Teodor Mihai, Monica-Cristina Pânzaru
Zitieren
APA
Ciobanu, C. G., Nucă, I., Popescu, R., Antoci, L. M., Caba, L., Ivanov, A. V., Cojocaru, K. A., Rusu, C., Mihai, C. T., & Pânzaru, M. C. (2023). Narrative Review: Update on the Molecular Diagnosis of Fragile X Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119206
Vancouver
Ciobanu CG, Nucă I, Popescu R, Antoci LM, Caba L, Ivanov AV, et al. Narrative Review: Update on the Molecular Diagnosis of Fragile X Syndrome. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119206
BibTeX
@article{Ciobanu2023,
author = {Ciobanu, Cristian-Gabriel and Nucă, Irina and Popescu, Roxana and Antoci, Lucian-Mihai and Caba, Lavinia and Ivanov, Anca Viorica and Cojocaru, Karina-Alexandra and Rusu, Cristina and Mihai, Cosmin-Teodor and Pânzaru, Monica-Cristina},
title = {Narrative Review: Update on the Molecular Diagnosis of Fragile X Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24119206}
}
EUVIMED